New directors bring decades of financial leadership and board experience to enhance strategic oversight of Return-to-Growth action plan and long-term value creationCHARLOTTE, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced the appointments of James (Jim) D. Forbes and Brian P. McKeon to its Board of Directors (the “Board”), effective February 27, 2026. Mr. Forbes is a veteran healthcare investment banker with 30 years of experi ...

SINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Antalpha Platform Holding Company (NASDAQ: ANTA) ("Antalpha" or the "Company"), a leading institutional digital asset financing platform, today announced that it will report its financial results for the fourth quarter and full year 2025 before the U.S. market open on March 3, 2026. The Company’s management team will hold a conference call at 8:00 A.M. U.S. Eastern Time on March 3, 2026 (or 9:00 P.M. Singapore Time on March 3, 2026) to discuss the financial resul ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Inspired Entertainment, Inc. ("Inspired" or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware and services, announced that it will report financial results for the fourth quarter and full year ended December 31, 2025 before the market opens on Tuesday, March 10, 2026. Inspired management will host a conference call and simultaneous webcast the same day at 8:30 a.m. ET / 12:30 p.m. in the UK to discuss the Company's resul ...

Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)• Significant improvement in PFS over combined SoC (HR: 0.37, p<0.05) Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026 SAN DIEGO, Feb. 24, 2026 (G ...

PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in the upcoming investor conferences in March as follows: UBS European Healthcare Conference Tuesday, March 3, 2026 (investor meetings only – no webcast)Leerink Partners Global Healthcare ConferenceMonday, March 9, 2026, at 10:00 am ET (webcast fireside chat)Barclays 28th Annual Global Healthcare Co ...

Boca Raton, FL, Feb. 24, 2026 (GLOBE NEWSWIRE) -- IB Capital is pleased to announce it served as exclusive M&A advisor to Benchmark Logistics LLC, and its wholly owned subsidiary, Triangle Warehouse, Inc., in their sale to TFI International Inc., which closed in February 2026. Headquartered in Minneapolis, Benchmark Logistics, together with Triangle Warehouse, provides dedicated transportation and warehouse services to a diverse customer base across the Upper Midwestern United States. TFI International Inc. ...

NEWBURYPORT, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported 2025 net income of $68.3 million, 15.8% higher than net income of $59.0 million for 2024. Adjusted net income grew 12.7% to $76.1 million. Net sales for the year ended December 31, 2025 were $602.8 million, 19.5% higher than 2024 sales of $504.4 million. GAAP and adjusted earnings p ...

PHILADELPHIA, PA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Art Technology Acquisition Corp. (NASDAQ:ARTCU) (the “Company”) announced today that, commencing February 27, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. The Class A ordinary shares and warrants that are separated will trade on the Nasdaq Global Market under the symbols “ARTC” and “ARTCW,” respectively. Those units not separa ...

NEW ALBANY, Ohio, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Commercial Vehicle Group (the “Company” or “CVG”) (NASDAQ: CVGI) will hold its quarterly conference call on Wednesday, March 11, 2026, at 8:30 a.m. ET, to discuss fourth quarter and full year 2025 financial results. CVG will issue a press release and presentation prior to the conference call. Toll-free participants dial (800) 549-8228 using conference code 51917. International participants dial (289) 819-1520 using conference code 51917. This call is being ...

Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026Improved balance sheet through multiple direct offerings; completed payments of outstanding debtHOUSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts ...